Azur Pharma Inc. Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB Two Marketed CNS Products With U.S. Revenues of $20 Million Two FDA Approved but Unlaunched Products
1/9/2009 9:56:19 AM
More...
|
Antares Pharma, Inc. (ANTR) Receives Milestone Payment and Additional Patent Related to Elestrin(R)
1/6/2009 8:44:32 AM
More...
|
Azur Pharma Enters Into Definitive Agreement With BioSante Pharmaceuticals, Inc. (BPAX) to Acquire U.S. Rights to Elestrin (TM)
12/4/2008 6:43:52 AM
More...
|
Azur Pharma and Elan Corporation PLC (ELN) (NYSE: ELN) Sign Agreement to Develop a Once-Daily Clozapine
11/10/2008 11:56:27 AM
More...
|
IntelGenx Technologies Corp. Forms Strategic Agreement with Azur Pharma to Develop Prenatal Vitamin Supplements Addressing a U.S. Market of $250 Million
1/7/2008 10:14:07 AM
More...
|
Azur Pharma Completes Equity Financing for US$48 Million
8/7/2007 9:44:29 AM
More...
|
Azur Pharma Announces the Acquisition of Pharmelle LLC; Adds 35 Person U.S. Sales Force
2/26/2007 10:18:40 AM
More...
|